Join to View Full Profile
2020 Santa Monica Blvd., Suite 600Santa Monica, CA 90404
Phone+1 310-829-5471
Fax+1 310-829-5471
Dr. Larson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2011 - 2013
University of ChicagoFellowship, Hematology and Medical Oncology, 2010 - 2011- University of ChicagoResidency, Internal Medicine, 2007 - 2010
University of Minnesota Medical SchoolClass of 2007
Certifications & Licensure
CA State Medical License 2011 - 2027
IL State Medical License 2007 - 2011
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Stem Cell Gene Therapy for Sickle Cell Disease Start of enrollment: 2014 Dec 01
Publications & Presentations
PubMed
- The Impact of Social Determinants of Health on Peripheral T Cell Lymphoma Outcomes: Treatment Center-Type Emerges as a Powerful Prognostic Indicator.Monica Mead, Beth Glenn, Joe Tuscano, Angshuman Saha, Sarah Larson
Clinical Lymphoma, Myeloma & Leukemia. 2025-03-01 - 18 citationsGeneration of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method.Yan-Ruide Li, Yang Zhou, Jiaji Yu, Yu Jeong Kim, Miao Li
Nature Biotechnology. 2025-03-01 - A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome.Guillermo Garcia-Manero, Manila Gaddh, Uwe Platzbecker, R Coleman Lindsley, Sarah M Larson
Annals of Hematology. 2025-03-01
Press Mentions
UCLA and Parker Institute Continue Collaboration to Advance Next-Generation Cancer ImmunotherapiesOctober 16th, 2024- New CAR T Approach Minimizes Resistance, Helps Avoid Relapse in Non-Hodgkin's B-cell LymphomaApril 10th, 2021
UCLA Opens Pioneering CAR T Clinical Trial Aimed at Extending the Lives of People Diagnosed with the Most Common Types of Lymphoma and LeukemiaOctober 16th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
